Breaking News, Financial News

Financial Report: Alexion 2Q11

Soliris sales jump 48% to $185.7 million.

Alexion 2Q11

2Q Revenues: $186.0 million (+48%)

2Q Earnings: $34.7 million (+60%)

YTD Revenues: $352.0 million (+45%)

YTD Earnings: $61.6 million (+4%)

Comments: Sales of Soliris (eculizumab) were up 48% to $185.7 million in the quarter. R&D expenses for the quarter were $35.6 million, up 50%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters